FDA Approved HIV Preventative Pill Marketed to Uninfected Public

John C. Martin, Chairman and Chief Executive Officer, who served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS and worked for competitors Bristol-Myers Squibb and Syntex Corporation.

Robin L. Washington, Senior Vice President and Chief Financial Officer who was a former accounting analyst for the Federal Reserve Bank of Chicago.

Kevin Young, Executive Vice President, Commercial Operations, who was appointed Commander of The British Empire for his service to the healthcare and pharmaceutical industries.

Margaret Hamburg, FDA commissioner, released a statement saying that the approval by the FDA “marks an important milestone in our fight against HIV.”

Marketed as a preventative for people who are at high risk of contracting HIV through sexual activies, Turvada is supported by public health advocates that believe this pill will slow down the spread of HIV. 

In America it is estimated that 1.2 million people have HIV. With this new antiviral drug, it is proposed that 240,000 HIV carriers will not be able to continue to spread the disease.

Gilead Sciences combined two separate drugs to create Truvada. The genetic engineering of the preventative pill is praised by the FDA to answer the assumption that condoms are not effective. The pharmaceutical corporations are working hard to convince the general public that their drugs are the only answer to our problems; whether with regard to healthcare or psychology, or simply controlling social behavior as with addiction vaccines.

The inception of HIV/AIDS began in the late 1970s when the World Health Organization (WHO) went into Africa under a smallpox vaccine initiative. Suddenly, in 1981, the first recorded incident of HIV was “discovered” in the same places where WHO had conducted the smallpox vaccine campaigns.

The United Nations (UN) says that the geographic spread of HIV/AIDS is mostly focused on black people in Africa and the Southeast Asia region. This bioweapon is a directed attack on the densely populated areas in underdeveloped nations.

According to Henry Kissinger, in the National Security Memorandum (NSSM 200):

De-population should be the highest priority of US foreign policy towards the Third World . . . Reduction of the rate of population in these States [Third World nations] is a matter of vital US national security.

Kissinger goes on to state that:

The US economy will require large and increasing amounts of minerals from abroad, especially from less developed countries.

The primary focus of this depopulation initiative was “economic interests of the US.”

Chris Collins, vice president of the Foundation for AIDS Research claims: 

I think it’s very good news. We need more prevention options to effectively tackle AIDS in the U.S. and globally.

Gilead Sciences has had Truvada within their arsenal of drugs since 2004 and purveyed it as a treatment for those infected with HIV. In 2010, research studies of the drug showed that it could also be used as a precautionary measure. When used with counseling and condoms, 42% of gay and bisexual males showed reduction in evidenced infections.

Globally, 2,500 men were studied regarding Truvada, and the researchers claim that this drug decreased the risk of infection by 75% and that this would make it a great preventative pill.

The FDA will now allow this drug to be used for preventative purposes. They stipulate that HIV-negative blood tests must be taken prior to prescription of Truvada. According to the packaging, Truvada “must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initial use and periodically during use.”